Pseudoprogression and Treatment Effect

Neurosurgery Clinics of North America

Volumn 23, Issue 2, 2012, Pages 277-287

  Jahangiri, Arman ^a   Aghi, Manish K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Glioblastoma; Imaging; Progression; Recurrence

Indexed keywords

3' FLUOROTHYMIDINE F 18; BEVACIZUMAB; CORTICOSTEROID; FERUMOXYTOL; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ANTIANGIOGENIC THERAPY; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DRUG METABOLISM; GLIOBLASTOMA; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSEUDOPROGRESSION; RADIATION NECROSIS; REVIEW; RISK FACTOR; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84858589242     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.01.002     Document Type: Review

References (99)

1. Clark A.J., Lamborn K.R., Butowski N.A., et al. Neurosurgical management and prognosis of patients with glioblastoma that progress during bevacizumab treatment. Neurosurgery 2011, 70(2):361-370.
2. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
3. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
4. Brandes A.A., Tosoni A., Franceschi E., et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 2009, 27:1275-1279.
5. Wick W., Stupp R., Beule A.C., et al. A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro Oncol 2008, 10:1019-1024.
6. Milano M.T., Okunieff P., Donatello R.S., et al. Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 2010, 78:1147-1155.
7. Oh J., Sahgal A., Sanghera P., et al. Glioblastoma: patterns of recurrence and efficacy of salvage treatments. Can J Neurol Sci 2011, 38:621-625.
8. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13:1253-1259.
9. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
10. Kumar A.J., Leeds N.E., Fuller G.N., et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000, 217:377-384.
11. Giglio P., Gilbert M.R. Cerebral radiation necrosis. Neurologist 2003, 9:180-188.
12. Yaman E., Buyukberber S., Benekli M., et al. Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. Clin Neurol Neurosurg 2010, 112:662-667.
13. Macdonald D.R., Cascino T.L., Schold S.C., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
14. Brandsma D., Stalpers L., Taal W., et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008, 9:453-461.
15. Wong C.S., Van der Kogel A.J. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 2004, 4:273-284.
16. Yang I., Aghi M.K. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol 2009, 6:648-657.
17. Sanghera P., Rampling R., Haylock B., et al. The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas. Clin Oncol (R Coll Radiol) 2011, [Epub ahead of print].
18. Young R.J., Gupta A., Shah A.D., et al. Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 2011, 76:1918-1924.
19. Brandes A.A., Franceschi E., Tosoni A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26:2192-2197.
20. Taal W., Brandsma D., de Bruin H.G., et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008, 113:405-410.
21. Danson S.J., Middleton M.R. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 2001, 1:13-19.
22. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
23. Chakravarti A., Erkkinen M.G., Nestler U., et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006, 12:4738-4746.
24. Park C.K., Kim J., Yim S.Y., et al. Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro Oncol 2011, 13:195-202.
25. Jeuken J.W., Cornelissen S.J., Vriezen M., et al. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 2007, 87:1055-1065.
26. Nygren A.O., Ameziane N., Duarte H.M., et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005, 33:e128.
27. Walker M.D., Alexander E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49:333-343.
28. Covarrubias D.J., Rosen B.R., Lev M.H. Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004, 9:528-537.
29. Bisdas S., Naegele T., Ritz R., et al. Distinguishing recurrent high-grade gliomas from radiation injury: a pilot study using dynamic contrast-enhanced MR imaging. Acad Radiol 2011, 18:575-583.
30. Marks J.E., Wong J. The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study. Prog Exp Tumor Res 1985, 29:210-218.
31. DeAngelis L.M. Brain tumors. N Engl J Med 2001, 344:114-123.
32. Moody D.M., Bell M.A., Challa V.R. Features of the cerebral vascular pattern that predict vulnerability to perfusion or oxygenation deficiency: an anatomic study. AJNR Am J Neuroradiol 1990, 11:431-439.
33. Alexiou G.A., Tsiouris S., Kyritsis A.P., et al. Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities. J Neurooncol 2009, 95:1-11.
34. Carvalho P.A., Schwartz R.B., Alexander E., et al. Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography. J Neurosurg 1992, 77:565-570.
35. Byrne T.N. Imaging of gliomas. Semin Oncol 1994, 21:162-171.
36. Leeds N.E., Jackson E.F. Current imaging techniques for the evaluation of brain neoplasms. Curr Opin Oncol 1994, 6:254-261.
37. Mullins M.E., Barest G.D., Schaefer P.W., et al. Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis. AJNR Am J Neuroradiol 2005, 26:1967-1972.
38. Marks J.E., Baglan R.J., Prassad S.C., et al. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 1981, 7:243-252.
39. Ruben J.D., Dally M., Bailey M., et al. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65:499-508.
40. Chamberlain M.C., Glantz M.J., Chalmers L., et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007, 82:81-83.
41. Nieder C., Andratschke N., Wiedenmann N., et al. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?. Strahlenther Onkol 2004, 180:401-407.
42. Kong D.S., Lee J.I., Park K., et al. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer 2008, 112:2046-2051.
43. Perry A., Schmidt R.E. Cancer therapy-associated CNS neuropathology: an update and review of the literature. Acta Neuropathol 2006, 111:197-212.
44. Lawrence Y.R., Li X.A., el Naqa I., et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys 2010, 76:S20-S27.
45. Sheline G.E., Wara W.M., Smith V. Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980, 6:1215-1228.
46. Tofilon P.J., Fike J.R. The radioresponse of the central nervous system: a dynamic process. Radiat Res 2000, 153:357-370.
47. Fajardo L.F. Is the pathology of radiation injury different in small vs large blood vessels?. Cardiovasc Radiat Med 1999, 1:108-110.
48. Gupta V.K., Jaskowiak N.T., Beckett M.A., et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002, 8:47-54.
49. Kim J.H., Chung Y.G., Kim C.Y., et al. Upregulation of VEGF and FGF2 in normal rat brain after experimental intraoperative radiation therapy. J Korean Med Sci 2004, 19:879-886.
50. Lin T., Genestier L., Pinkoski M.J., et al. Role of acidic sphingomyelinase in Fas/CD95-mediated cell death. J Biol Chem 2000, 275:8657-8663.
51. Rodemann H.P., Blaese M.A. Responses of normal cells to ionizing radiation. Semin Radiat Oncol 2007, 17:81-88.
52. Miyashita T., Krajewski S., Krajewska M., et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994, 9:1799-1805.
53. Fuks Z., Persaud R.S., Alfieri A., et al. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 1994, 54:2582-2590.
54. Haimovitz-Friedman A., Balaban N., McLoughlin M., et al. Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res 1994, 54:2591-2597.
55. Sathornsumetee S., Cao Y., Marcello J.E., et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008, 26:271-278.
56. Salmaggi A., Eoli M., Frigerio S., et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol 2003, 62:297-303.
57. Takano S., Yoshii Y., Kondo S., et al. Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996, 56:2185-2190.
58. Nam D.H., Park K., Suh Y.L., et al. Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 2004, 11:863-869.
59. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
60. Inai T., Mancuso M., Hashizume H., et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004, 165:35-52.
61. Du R., Lu K.V., Petritsch C., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
62. Kunkel P., Ulbricht U., Bohlen P., et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001, 61:6624-6628.
63. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787.
64. Rubenstein J.L., Kim J., Ozawa T., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2:306-314.
65. Rees J.H., Smirniotopoulos J.G., Jones R.V., et al. Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics 1996, 16:1413-1438. [quiz: 1462-3].
66. Pope W.B., Young J.R., Ellingson B.M. Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Curr Neurol Neurosci Rep 2011, 11:336-344.
67. Brandsma D., van den Bent M.J. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009, 22:633-638.
68. Clarke J.L., Chang S. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep 2009, 9:241-246.
69. Gonzalez J., Kumar A.J., Conrad C.A., et al. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007, 67:323-326.
70. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
71. Wen P.Y., Macdonald D.R., Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010, 28:1963-1972.
72. Mehta A.I., Kanaly C.W., Friedman A.H., et al. Monitoring radiographic brain tumor progression. Toxins (Basel) 2011, 3:191-200.
73. Kim Y.H., Oh S.W., Lim Y.J., et al. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg 2010, 112:758-765.
74. McPherson C.M., Warnick R.E. Results of contemporary surgical management of radiation necrosis using frameless stereotaxis and intraoperative magnetic resonance imaging. J Neurooncol 2004, 68:41-47.
75. Gauvain K.M., McKinstry R.C., Mukherjee P., et al. Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol 2001, 177:449-454.
76. Guo Y., Cai Y.Q., Cai Z.L., et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 2002, 16:172-178.
77. Sugahara T., Korogi Y., Kochi M., et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999, 9:53-60.
78. Koh D.M., Collins D.J. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007, 188:1622-1635.
79. Hein P.A., Eskey C.J., Dunn J.F., et al. Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury. AJNR Am J Neuroradiol 2004, 25:201-209.
80. Asao C., Korogi Y., Kitajima M., et al. Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence. AJNR Am J Neuroradiol 2005, 26:1455-1460.
81. Sundgren P.C., Fan X., Weybright P., et al. Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging 2006, 24:1131-1142.
82. Verma R., Zacharaki E.I., Ou Y., et al. Multiparametric tissue characterization of brain neoplasms and their recurrence using pattern classification of MR images. Acad Radiol 2008, 15:966-977.
83. Gerstner E.R., Sorensen A.G. Diffusion and diffusion tensor imaging in brain cancer. Semin Radiat Oncol 2011, 21:141-146.
84. Xu J.L., Li Y.L., Lian J.M., et al. Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging. Neuroradiology 2010, 52:1193-1199.
85. Schlemmer H.P., Bachert P., Herfarth K.K., et al. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR Am J Neuroradiol 2001, 22:1316-1324.
86. Smith E.A., Carlos R.C., Junck L.R., et al. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 2009, 192:W45-W52.
87. Zeng Q.S., Li C.F., Liu H., et al. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys 2007, 68:151-158.
88. Zeng Q.S., Li C.F., Liu H., et al. Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury. J Neurooncol 2007, 84:63-69.
89. Sugahara T., Korogi Y., Tomiguchi S., et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000, 21:901-909.
90. Cha S., Knopp E.A., Johnson G., et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000, 21:881-890.
91. Di Costanzo A., Pollice S., Trojsi F., et al. Role of perfusion-weighted imaging at 3 Tesla in the assessment of malignancy of cerebral gliomas. Radiol Med 2008, 113:134-143.
92. Hu L.S., Baxter L.C., Smith K.A., et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009, 30:552-558.
93. Gahramanov S., Raslan A.M., Muldoon L.L., et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2011, 79:514-523.
94. Yang I., Huh N.G., Smith Z.A., et al. Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy. Neurosurg Clin N Am 2010, 21:181-186.
95. Di Chiro G., Oldfield E., Wright D.C., et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 1988, 150:189-197.
96. Doyle W.K., Budinger T.F., Valk P.E., et al. Differentiation of cerebral radiation necrosis from tumor recurrence by [18F]FDG and 82Rb positron emission tomography. J Comput Assist Tomogr 1987, 11:563-570.
97. Ricci P.E., Karis J.P., Heiserman J.E., et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?. AJNR Am J Neuroradiol 1998, 19:407-413.
98. Jacobs A.H., Thomas A., Kracht L.W., et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005, 46:1948-1958.
99. Chen W., Cloughesy T., Kamdar N., et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005, 46:945-952.